Who's speaking at this Webinar?
Co-Founder & Chief Executive, Beckley Psytech
The promising medical qualities of psychedelics, such as LSD and psilocybin “magic” mushrooms, have been under-researched for decades owing to prevalent misconceptions about the safety and efficacy of these currently illegal drugs.
But recent years have seen significant progress, with the game-changing potential for psychedelic medicines to treat conditions ranging from depression and anxiety to PTSD gaining increasing recognition and momentum.
In this presentation, Cosmo Feilding-Mellen, co-founder and chief executive of Oxford-based psychedelic medicine company Beckley Psytech will take stock of the current psychedelic innovation landscape and the vast potential for psychedelic treatments in healthcare. He will take a deep dive into the conditions that Beckley and other research organisations hope to address with psychedelic therapeutics, and the outlook for this brave new world.
Furthermore, Cosmo will discuss the company’s exciting research programmes, from its exploration of synthetic compound 5-MeO-DMT to a landmark clinical trial of the effects of psilocybin on short-lasting unilateral neuralgiform headache attacks (SUNHA).
During this webinar we will discuss:
- The unmet needs where psychedelic medicines may have a real impact
- The focus of current psychedelic research efforts and where the most promising progress is being made
- The outlook for psychedelic medicines and assisted psychotherapy as part of the healthcare system of the future